Neuer SGLT-2-Inhibitor
| eröffnet am: | 27.06.11 20:15 von: | ellogo2 |
| neuester Beitrag: | 25.04.21 00:44 von: | Franziskabrqpa |
| Anzahl Beiträge: | 1120 | |
| Leser gesamt: | 387241 | |
| davon Heute: | 151 | |
bewertet mit 8 Sternen |
||
|
|
||
30.09.15 17:32
#352
bazooka73
Ich hoffe...
...sie senden jetzt dann nicht auch noch eine "Richtigstellung" zum restlichen Mumpitz hinterher. Das wäre peinlich, vor allem, weil man sich soeben eine PR-Agentur angelacht hat...
01.10.15 07:38
#354
Tuedi2005
Nur mal zur Info:
Pari wäre beim aktuellen SK in Kanada (0,165 $) etwa 0,110 €.
Immer unter Pari ist ja irgendwie auch blöd.
Immer unter Pari ist ja irgendwie auch blöd.
02.10.15 12:24
#355
fklook
wollte nur mal guten Tag sagen
bin jetzt auch im Kreis der Sironas und wünsche uns allen viel Glück.
02.10.15 13:18
#356
Tuedi2005
Mittags schon 300 k gehandelt.
Nicht übel...und alles schön unter Pari. Glückwunsch.
Sooo günstig dürfte es nicht mehr lange bleiben mMn.
Sooo günstig dürfte es nicht mehr lange bleiben mMn.
03.10.15 16:17
#357
Tuedi2005
Noch mal zur Auffrischung:
http://www.sironabiochem.com/...eutical-companies-for-lead-compounds/
Sirona Biochem CEO Update: Significant Interest from Top Cosmetic and Pharmaceutical Companies for Lead Compounds
Vancouver, British Columbia – June 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) today provided a business update.
Dear Shareholders,
I would like to provide an update on our progress and to communicate the corporate strategic priorities that will deliver value to our shareholders in the near and long term.
Recently we announced the development of the safest, most effective skin lightener in the world, with SBM-TFC-1067. Our main focus is to license this asset to a major corporation with a global commercial and R&D infrastructure in Japan and Asia-Pacific. These regions represent the vast majority of the $20 billion skin lightening market.
SBM-TFC-1067 has attracted significant interest up to the level of material transfer agreements from nine of the top cosmetic and pharmaceutical companies that dominate the skin care market. The growing problem with current treatments is that they are either hydroquinone based, or release hydroquinone. Hydroquinone has known safety risks associated with its use, and there is evidence that it may be a potential carcinogen. It has been banned in Japan, the European Union, Australia, Korea, and also found on Canada’s toxic substances list.
Sirona has developed a solution for the problem, since there is zero hydroquinone released with SBM-TFC-1067. A major corporation could establish a large share of the skin lightening market through a licensing agreement with Sirona. Furthermore, this asset does not directly compete with SBM-TFC-849, which has been licensed to Valeant/Obagi, with a focus on the physician-dispensed channel in the US.
Our anti-aging and regenerative medicine lead candidate, SBM-TFC-837, has delivered breakthrough scientific results demonstrating significant protection in fibroblasts against the stressed conditions of nutrient deprivation, UV irradiation and most recently, oxidative stress. There is ongoing development of this asset to further characterize the multiple mechanisms by which this glycoprotein exerts its positive effects. There are eight major corporations that have expressed interest in this asset and, most importantly, we have obtained the commitment from a major corporation to execute a material transfer agreement to test our compound in their own facility.
The anti-inflammatory project is undergoing compound optimization to ensure maximum commercial viability. In 2016, the project will be transferred to our partner, Bloom Burton, to be further developed as a pharmaceutical.
For our ongoing collaborations, we continue to provide tech transfer consultations to both Valeant/Obagi and Fosun/Wanbang Biopharmaceuticals as they continue the development of SBM-TFC-849 for skin lightening in the physician dispensed channel in the US and SBM-TFC-039 for type 2 diabetes in China.
The company continues to maintain a healthy balance sheet despite being over a year since the last private placement. We recently generated an additional $400,000 as a result of shareholders exercising approximately 2.8 million warrants and our investor base was expanded through a successful European road show.
Moving forward, we anticipate at least one successful licensing agreement by the end of the year, which would be structured to include upfront, milestone and approval payments at each stage of clinical testing, scale-up and formulation, followed by a royalty stream.
In the near term, we will be presenting and participating at BIO International in Philadelphia, attending the World Congress of Dermatology in Vancouver, attending Cosmetics 360 in Paris and BIO Europe in Munich.
Looking back, over the last 6 months, Sirona Biochem has completed the following:
Tests completed on our third skin lightener and creation of a comprehensive non-confidential slide deck which is being actively reviewed by leading global pharma organizations.
Advanced the anti-aging and cell preservation projects into cell studies, which are also being reviewed by global pharma organizations.
Entered into several partnering discussions with leading cosmetic and pharmaceutical companies for testing of both the skin lightener and anti-aging compound.
Presented at 5 pharma/biotech conferences, increasing the awareness of the assets within our pipeline.
Secured funding from the French organization BPI and region Haute Normandie for the anti-aging project.
We remain committed to our goal of becoming a global leader in commercializing carbohydrate chemistry by providing leading cosmetic and pharmaceutical companies with innovative products.
With your continued support and our ongoing efforts, together we can realize this goal.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
Sirona Biochem CEO Update: Significant Interest from Top Cosmetic and Pharmaceutical Companies for Lead Compounds
Vancouver, British Columbia – June 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) today provided a business update.
Dear Shareholders,
I would like to provide an update on our progress and to communicate the corporate strategic priorities that will deliver value to our shareholders in the near and long term.
Recently we announced the development of the safest, most effective skin lightener in the world, with SBM-TFC-1067. Our main focus is to license this asset to a major corporation with a global commercial and R&D infrastructure in Japan and Asia-Pacific. These regions represent the vast majority of the $20 billion skin lightening market.
SBM-TFC-1067 has attracted significant interest up to the level of material transfer agreements from nine of the top cosmetic and pharmaceutical companies that dominate the skin care market. The growing problem with current treatments is that they are either hydroquinone based, or release hydroquinone. Hydroquinone has known safety risks associated with its use, and there is evidence that it may be a potential carcinogen. It has been banned in Japan, the European Union, Australia, Korea, and also found on Canada’s toxic substances list.
Sirona has developed a solution for the problem, since there is zero hydroquinone released with SBM-TFC-1067. A major corporation could establish a large share of the skin lightening market through a licensing agreement with Sirona. Furthermore, this asset does not directly compete with SBM-TFC-849, which has been licensed to Valeant/Obagi, with a focus on the physician-dispensed channel in the US.
Our anti-aging and regenerative medicine lead candidate, SBM-TFC-837, has delivered breakthrough scientific results demonstrating significant protection in fibroblasts against the stressed conditions of nutrient deprivation, UV irradiation and most recently, oxidative stress. There is ongoing development of this asset to further characterize the multiple mechanisms by which this glycoprotein exerts its positive effects. There are eight major corporations that have expressed interest in this asset and, most importantly, we have obtained the commitment from a major corporation to execute a material transfer agreement to test our compound in their own facility.
The anti-inflammatory project is undergoing compound optimization to ensure maximum commercial viability. In 2016, the project will be transferred to our partner, Bloom Burton, to be further developed as a pharmaceutical.
For our ongoing collaborations, we continue to provide tech transfer consultations to both Valeant/Obagi and Fosun/Wanbang Biopharmaceuticals as they continue the development of SBM-TFC-849 for skin lightening in the physician dispensed channel in the US and SBM-TFC-039 for type 2 diabetes in China.
The company continues to maintain a healthy balance sheet despite being over a year since the last private placement. We recently generated an additional $400,000 as a result of shareholders exercising approximately 2.8 million warrants and our investor base was expanded through a successful European road show.
Moving forward, we anticipate at least one successful licensing agreement by the end of the year, which would be structured to include upfront, milestone and approval payments at each stage of clinical testing, scale-up and formulation, followed by a royalty stream.
In the near term, we will be presenting and participating at BIO International in Philadelphia, attending the World Congress of Dermatology in Vancouver, attending Cosmetics 360 in Paris and BIO Europe in Munich.
Looking back, over the last 6 months, Sirona Biochem has completed the following:
Tests completed on our third skin lightener and creation of a comprehensive non-confidential slide deck which is being actively reviewed by leading global pharma organizations.
Advanced the anti-aging and cell preservation projects into cell studies, which are also being reviewed by global pharma organizations.
Entered into several partnering discussions with leading cosmetic and pharmaceutical companies for testing of both the skin lightener and anti-aging compound.
Presented at 5 pharma/biotech conferences, increasing the awareness of the assets within our pipeline.
Secured funding from the French organization BPI and region Haute Normandie for the anti-aging project.
We remain committed to our goal of becoming a global leader in commercializing carbohydrate chemistry by providing leading cosmetic and pharmaceutical companies with innovative products.
With your continued support and our ongoing efforts, together we can realize this goal.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
03.10.15 16:55
#358
Tuedi2005
Und übrigens:
das Kursziel von First Berlin von 0,91 $ beruht nur auf den beiden Vereinbarungen mit Wanbang - für den chinesischen Markt - und Obagi für den ersten Hautaufheller 849.
Das ganze wurde dann noch sehr konservativ gerechnet.
So: und jetzt packen wir mal den neuen Hautaufheller, SGLT-2 für den Rest der Welt und das Anti-Aging-Mittel dazu...und dann wird mir ehrlich gesagt schon ziemlich schwindelig.
Und selbt das iat ja noch längst nicht alles, was Sirona im Köcher hat.
Das ganze wurde dann noch sehr konservativ gerechnet.
So: und jetzt packen wir mal den neuen Hautaufheller, SGLT-2 für den Rest der Welt und das Anti-Aging-Mittel dazu...und dann wird mir ehrlich gesagt schon ziemlich schwindelig.
Und selbt das iat ja noch längst nicht alles, was Sirona im Köcher hat.
05.10.15 15:00
#359
Deni86
Kursziele
Wenn diese theoretischen Annahmen auch nur annähernd in der Realität eintreffen würden, wäre schon nicht so verkehrt. Ich glaube dazu muss man aber mindestens noch ein halbes Jahr bis 1 Jahr lang warten, vorher kommt hier mMn nicht viel dabei rum. Ich würde es natürlich allen Investierten gönnen, aber einen Kurs der höher als 0,15 Cent steht, werden wir mMn vor März 2016 nicht sehen..
05.10.15 15:02
#360
bazooka73
ACHTUNG
Bester Tuedi: Deine Euphorie in Ehren, aber bitte bei der Realität und den Tatsachen bleiben. Mit diesen kühnen Aussagen hast Du sonst sehr bald den Pumper-Stempel aufgedrückt.
1. In der Evaluation von First Berlin haben sie beim SGLT2 Inhibitor sowohl Asien WIE AUCH Rest of the World berücksichtigt (CN $21 Mio, RoW $58 Mio).
2. Für den Hautaufheller TFC-849 gilt: Diese Bewertung ist mit TFC-1067 Makulatur. Es wäre fahrlässig zu glauben, dass Obagi mit diesem Wirkstoff noch den gleichen Umsatz erzielen wird, da man ja insbesondere dafür auch einen neuen Verwendungsbereich definiert hat (über Verschreibung via Ärzte anstatt reines Consumer-Retailprodukt)
Gehe davon aus, dass vielleicht noch 10% von dem erwartet werden kann, was in der Bewertung steht ($110 Mio.)
3. Richtig, den TFC-1067 wird die Bewertung dann wieder erhöhen. Nur: Die Bäume wachsen nicht in den Himmel. Ich komme bei meiner Berechnung am Ende auf ca. $1.39/Share anstatt $0.91.
Insbesondere gilt aber: Noch ist nichts unterzeichnet.
4. Es kommt ebenfalls noch Anti-Aging (inshallah). Wie sich das finanziell auswirken wird und was man dereinst für Revenues erwarten kann, das steht zur Zeit alles in den Sternen.
Übrigens: Die in der Präsentation erwähnten Revenues von Total $879 Mio. (Upfront, Milestones, Royalties) für TFC-1067 wurden übrigens von BloomBurton ermittelt und basieren selbstredend nicht auf irgendwelchen bereits - oder zumindest vermeintlich - vorliegenden Angeboten.
The road is long, so stay long!
1. In der Evaluation von First Berlin haben sie beim SGLT2 Inhibitor sowohl Asien WIE AUCH Rest of the World berücksichtigt (CN $21 Mio, RoW $58 Mio).
2. Für den Hautaufheller TFC-849 gilt: Diese Bewertung ist mit TFC-1067 Makulatur. Es wäre fahrlässig zu glauben, dass Obagi mit diesem Wirkstoff noch den gleichen Umsatz erzielen wird, da man ja insbesondere dafür auch einen neuen Verwendungsbereich definiert hat (über Verschreibung via Ärzte anstatt reines Consumer-Retailprodukt)
Gehe davon aus, dass vielleicht noch 10% von dem erwartet werden kann, was in der Bewertung steht ($110 Mio.)
3. Richtig, den TFC-1067 wird die Bewertung dann wieder erhöhen. Nur: Die Bäume wachsen nicht in den Himmel. Ich komme bei meiner Berechnung am Ende auf ca. $1.39/Share anstatt $0.91.
Insbesondere gilt aber: Noch ist nichts unterzeichnet.
4. Es kommt ebenfalls noch Anti-Aging (inshallah). Wie sich das finanziell auswirken wird und was man dereinst für Revenues erwarten kann, das steht zur Zeit alles in den Sternen.
Übrigens: Die in der Präsentation erwähnten Revenues von Total $879 Mio. (Upfront, Milestones, Royalties) für TFC-1067 wurden übrigens von BloomBurton ermittelt und basieren selbstredend nicht auf irgendwelchen bereits - oder zumindest vermeintlich - vorliegenden Angeboten.
The road is long, so stay long!
05.10.15 15:50
#361
Tuedi2005
@bazooka73
Danke fürs freundliche Einfangen.
Da sind wohl tatsächlich die Euphorie-Gäule etwas mit mir durchgegangen.
Was unter dem Strich bleibt, ist aus meiner Sicht eine durchaus realistische Chance auf hohe Kursgewinne bei derzeit immer noch sehr hohem Risiko.
Da sind wohl tatsächlich die Euphorie-Gäule etwas mit mir durchgegangen.
Was unter dem Strich bleibt, ist aus meiner Sicht eine durchaus realistische Chance auf hohe Kursgewinne bei derzeit immer noch sehr hohem Risiko.
06.10.15 11:38
#362
fklook
fakt
ist hier muss keiner in die Aktie rein getrieben werden und aus dem ASK kaufen. Viel wichtiger wäre das das BID Orderbuch eine Absicherung nach unten bildet und zeigt das gelauert wird.
Würde dem ein oder anderen auch ein bisschen Nervosität nehmen und dann kommt was kommen soll.
Die Fakten liegen auf dem Tisch und sobald es nicht nur Prognosen sind sonder unterschriebene Verträge, wird sie los renne . Wenn alles nur heiße Luft war wissen wir auch was passiert.
HOCH RISIKO Investition würde mein Vater sagen mit großen Chancen in beide Richtungen.
Würde dem ein oder anderen auch ein bisschen Nervosität nehmen und dann kommt was kommen soll.
Die Fakten liegen auf dem Tisch und sobald es nicht nur Prognosen sind sonder unterschriebene Verträge, wird sie los renne . Wenn alles nur heiße Luft war wissen wir auch was passiert.
HOCH RISIKO Investition würde mein Vater sagen mit großen Chancen in beide Richtungen.
06.10.15 19:14
#363
Tuedi2005
Hmmm, endlich mal wieder
ein bißchen mehr Volumen in Kanada. Gut so :-)
07.10.15 09:40
#364
bazooka73
Aktienbewertung SBM
Nachfolgend finden die Interessierten auf "vielseitigen" Wunsch noch eine Neuberechnung des Aktienpreises von Sirona Biochem basierend auf der Bewertung durch First Berlin in ihrem Analyst Report vom Januar diesen Jahres:
https://drive.google.com/open?id=0B5wtBlQno1_ENUotanRGdW5ieTA
Nur meine Meinung.
07.10.15 13:24
#365
Tuedi2005
Die Berechnung von bazooka
sollte mindestens mal einen Anhalt geben, wo es kurstechnisch hingehen könnte. Alles noch nicht safe, aber die Chancen stehen mehr als gut, finde ich. Immerhin gibt es ja die Vereinbarungen mit Wanbang und Obagi...und auf den großen Lizenz-Deal , der nach Aussage der Firmenleitung kommen WIRD, warten wir im Moment noch.
Und die Berechnung berücksichtigt ja noch nicht den Anti-Aging-Bereich, von dem ja viele glauben, dass er der kommerziell vielversprechendste Bereich wird (ich muss aufpassen, dass ich nicht schon wieder zu euphorisch werde).
Und die Berechnung berücksichtigt ja noch nicht den Anti-Aging-Bereich, von dem ja viele glauben, dass er der kommerziell vielversprechendste Bereich wird (ich muss aufpassen, dass ich nicht schon wieder zu euphorisch werde).
09.10.15 10:56
#366
Tuedi2005
Neues Gerücht aus dem Stockhouse:
Rumor #1 Shiseido!
Shiseido, a big Asian market brand, is one of the many large companies at 360 Innovations.
I've heard that this was possibly the large company they were talking about in the mid September presentation for the skin lightener? These large brands don't want to be left behnd when innovations like this present themselves.
SBM already have guys on board, the rest will be playing catch up.
Anything less than 18 cents for this stock is a no-brainer and once we break through the 18 cents, 30 cents is the next resistance point. And as we saw in late August, this is a great defensive play if the global markets correct (some stock are WAY overvalued). SBM at 17 cents s WAY undervalued.
Patience people, patience.
Read more at http://www.stockhouse.com/companies/bullboard/...#QUbQcHr5sVRU0Vmf.99
Shiseido, a big Asian market brand, is one of the many large companies at 360 Innovations.
I've heard that this was possibly the large company they were talking about in the mid September presentation for the skin lightener? These large brands don't want to be left behnd when innovations like this present themselves.
SBM already have guys on board, the rest will be playing catch up.
Anything less than 18 cents for this stock is a no-brainer and once we break through the 18 cents, 30 cents is the next resistance point. And as we saw in late August, this is a great defensive play if the global markets correct (some stock are WAY overvalued). SBM at 17 cents s WAY undervalued.
Patience people, patience.
Read more at http://www.stockhouse.com/companies/bullboard/...#QUbQcHr5sVRU0Vmf.99
09.10.15 11:02
#367
Moneyplus
Wenn da was dran wäre
dann BOOOOMMMMM.
Shiseido war schon immer mein absoluter Favorit für den skin lightener.
Alleine schon, weil Japan der Hauptumsatzbringer hierfür wäre.
Abwarten und Daumen drücken.
Shiseido war schon immer mein absoluter Favorit für den skin lightener.
Alleine schon, weil Japan der Hauptumsatzbringer hierfür wäre.
Abwarten und Daumen drücken.
09.10.15 11:02
#368
Tuedi2005
Shiseido für den perfekten Hautaufheller
wäre ein super Lizenznehmer.
Wenn dann noch L'Oreal für die Anti-Aging-Produkte gewonnen werden könnte...
Wenn dann noch L'Oreal für die Anti-Aging-Produkte gewonnen werden könnte...
09.10.15 11:03
#369
Tuedi2005
Börse ist zwar kein Wunschkonzert...
aber man wird ja mal träumen dürfen :-)
09.10.15 11:03
#370
Moneyplus
Das wäre
dann der Jackpot.
Aber alles noch Träumereien (wobei nicht unwahrscheinlich)
Aber alles noch Träumereien (wobei nicht unwahrscheinlich)
10.10.15 10:52
#371
JoeUp
15. + 16. Oktober 2015, Paris
http://www.finanznachrichten.de/...60-konferenz-in-paris-teil-016.htm
http://www.finanznachrichten.de/...60-konferenz-in-paris-teil-016.htm
10.10.15 21:32
#372
Tuedi2005
Shiseido wird in der Präsentation
vom September nicht erwähnt...obwohl sie doch eigentlich eine ziemlich logische Wahl für den neuen Hautaufheller wären.
Zufall ? Oder vielleicht ja sogar Absicht, um mal eben so vom eigentlichen Ziel abzulenken ?
Zufall ? Oder vielleicht ja sogar Absicht, um mal eben so vom eigentlichen Ziel abzulenken ?
11.10.15 09:19
#373
Tuedi2005
@JoeUp
wenn sie den Wettbewerb gewinnen könnten, wäre das schon eine tolle Sache und würde ihnen sicherlich ziemlich viel Aufmerksamkeit in der Branche bringen.
Gerade die Anti-Aging-Produkte könnten auf lange Sicht DIE Cash-Cow des Unternehmens werden !
Gerade die Anti-Aging-Produkte könnten auf lange Sicht DIE Cash-Cow des Unternehmens werden !
12.10.15 13:05
#374
Tuedi2005
Guter Lesestoff:
http://www.prweb.com/releases/skin_lighteners/...ons/prweb2489104.htm
Global Skin Lighteners Market to Reach $10 Billion by 2015, According to New Report by Global Industry Analysts
GIA announces the release of a comprehensive global report on Skin Lighteners market. Globalization and cultural factors are major contributors to the growing desire for lighter skin tone among consumers. The world market for skin lighteners is projected to reach $10 billion by the year 2015, driven by the expanding demand for products that enhance skin color and prevent aging.
Skin Lighteners: A Global Strategic Business Report
San Jose, CA (PRWEB) June 22, 2009
Skin whitening is one of the rapidly growing segments of the global beauty industry. Global skin whitening market holds vast growth potential, with maximum opportunities emerging from the rapidly expanding Asian markets. Skin lightening products that prevent or inhibit pigmentation (including brown spots and freckles) and consist of anti-aging features are gaining popularity, particularly among customers in the western world. Although skin-whitening products were initially aimed at facial care, the trend has changed with companies offering products for overall skincare. Another trend witnessed in the skin lighteners market is the introduction of whitening products for men.
Japan dominates the global skin lighteners market with the lion's share, as stated in the new market research report. The market for skin lighteners in Asia-Pacific is projected to cross the $2.0 billion mark by 2012, driven by the fast growing markets of China and India. Apart from Asia, western countries such as the United States and the United Kingdom are emerging as potential markets for skin whitening products. The growing proportion of ethnic groups (Asians, Hispanics and African Americans) in these regions is a major contributor to the enhanced demand for skin lighteners.
Ability to identify regional preferences that are often influenced by cultural and ethnic factors is a major pre-requisite for global manufacturers to ensure competitive presence in various markets. Varying perceptions of customers from different parts of the world contribute to the demand for different types of products. While the western world considers anti-aging to be a major criterion for defining beauty, the same is associated with skin color in several Asian countries. Such factors determine marketing, promotional and distribution strategies adopted by global companies. Major players operating in the skin lighteners market include Beiersdorf AG, CavinKare Pvt. Ltd., Clarins SA, E.T. Browne Drug Company Inc., Elder Health Care Ltd., Emami Limited, Hindustan Unilever Ltd, Kao Corporation, Shiseido Company Limited, Procter & Gamble, and Jolen Inc.
The report titled "Skin Lighteners: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a review of market trends, competitive scenario, product introductions/innovations, and recent industry activity. The report analyzes market data and analytics for the following regions - United States, Japan, Europe, Asia-Pacific, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Skin_Lighteners_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Skin Lighteners Market to Reach $10 Billion by 2015, According to New Report by Global Industry Analysts
GIA announces the release of a comprehensive global report on Skin Lighteners market. Globalization and cultural factors are major contributors to the growing desire for lighter skin tone among consumers. The world market for skin lighteners is projected to reach $10 billion by the year 2015, driven by the expanding demand for products that enhance skin color and prevent aging.
Skin Lighteners: A Global Strategic Business Report
San Jose, CA (PRWEB) June 22, 2009
Skin whitening is one of the rapidly growing segments of the global beauty industry. Global skin whitening market holds vast growth potential, with maximum opportunities emerging from the rapidly expanding Asian markets. Skin lightening products that prevent or inhibit pigmentation (including brown spots and freckles) and consist of anti-aging features are gaining popularity, particularly among customers in the western world. Although skin-whitening products were initially aimed at facial care, the trend has changed with companies offering products for overall skincare. Another trend witnessed in the skin lighteners market is the introduction of whitening products for men.
Japan dominates the global skin lighteners market with the lion's share, as stated in the new market research report. The market for skin lighteners in Asia-Pacific is projected to cross the $2.0 billion mark by 2012, driven by the fast growing markets of China and India. Apart from Asia, western countries such as the United States and the United Kingdom are emerging as potential markets for skin whitening products. The growing proportion of ethnic groups (Asians, Hispanics and African Americans) in these regions is a major contributor to the enhanced demand for skin lighteners.
Ability to identify regional preferences that are often influenced by cultural and ethnic factors is a major pre-requisite for global manufacturers to ensure competitive presence in various markets. Varying perceptions of customers from different parts of the world contribute to the demand for different types of products. While the western world considers anti-aging to be a major criterion for defining beauty, the same is associated with skin color in several Asian countries. Such factors determine marketing, promotional and distribution strategies adopted by global companies. Major players operating in the skin lighteners market include Beiersdorf AG, CavinKare Pvt. Ltd., Clarins SA, E.T. Browne Drug Company Inc., Elder Health Care Ltd., Emami Limited, Hindustan Unilever Ltd, Kao Corporation, Shiseido Company Limited, Procter & Gamble, and Jolen Inc.
The report titled "Skin Lighteners: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a review of market trends, competitive scenario, product introductions/innovations, and recent industry activity. The report analyzes market data and analytics for the following regions - United States, Japan, Europe, Asia-Pacific, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Skin_Lighteners_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
12.10.15 13:10
#375
Tuedi2005
Besonders bemerkenswert finde ich
den folgenden Abschnitt:
While the western world considers anti-aging to be a major criterion for defining beauty, the same is associated with skin color in several Asian countries. Such factors determine marketing, promotional and distribution strategies adopted by global companies. Major players operating in the skin lighteners market include Beiersdorf AG, CavinKare Pvt. Ltd., Clarins SA, E.T. Browne Drug Company Inc., Elder Health Care Ltd., Emami Limited, Hindustan Unilever Ltd, Kao Corporation, Shiseido Company Limited, Procter & Gamble, and Jolen Inc.
Also: die westliche Welt hat es auf Anti-Aging als wesentliches Schönheitsmerkmal abgesehen und die asiatischen Länder auf die Hautaufheller.
Und für beide Mega-Trends hat Sirona Biochem innovative, möglicherweise bahnbrechende Produkte im Köcher.
Und die Industrie hat viel Geld, um sich in solche Produkte einzukaufen.
Passt doch nicht schlecht zusammen, würde ich meinen.